Category Archives: Stem Cell Research

LONDON--(BUSINESS WIRE)--The stem cell therapy market is expected to grow by USD 588.22 mn, progressing at a CAGR of almost 7% during the forecast period.

Click & Get Free Sample Report in Minutes

The increase in awareness of stem cell therapy is one of the major factors propelling market growth. However, factors such as the high cost of clinical trials will hamper the market growth.

More details: https://www.technavio.com/report/stem-cell-therapy-market-industry-analysis

Stem Cell Therapy Market: Type Landscape

Based on the type, the allogeneic transplants segment is expected to witness lucrative growth during the forecast period.

Stem Cell Therapy Market: Geographic Landscape

By geography, North America is going to have a lucrative growth during the forecast period. About 51% of the markets overall growth is expected to originate from North America. The US and Canada are the key markets for the stem cell therapy market in North America.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Related Reports on Health Care Include:

Companies Covered:

What our reports offer:

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original post:
Insights on the Global Stem Cell Therapy Market 2020-2024: COVID-19 Analysis, Drivers, Restraints, Opportunities, and Threats - Technavio - Business...

The lab of KrisSaha at the University of WisconsinMadison has developed an innovative combination of gene-editing tools and computational simulations that can be used to develop new strategies for editing genes associated with genetic disorders.

In proof-of-concept experiments, the labs researchers efficiently corrected multiple mutations responsible for a rare metabolic disorder, known as Pompe disease, in cells containing the disease-causing errors. They also used computer simulations to design the ideal gene-editing approach for treating human patients, a boon for rare disorders like Pompe disease that lack useful animal models.

Their promising platform advances the CRISPR genome-editing field and could lead to effective treatments for many diseases, not just Pompe disease.

The exact mutations seen in the Pompe patients are not in an existing animal model, so we cannot do all of the preclinical studies that we would like to do in order to evaluate the safety and efficacy of different genome editing strategies, says Saha, a professor of biomedical engineering at UWMadisons Wisconsin Institute for Discovery. We need a way to think about how we go from patient material to a therapy without having to build an animal model, a process that takes months to years and hundreds of thousands of dollars.

The lab of Kris Saha (standing) has developed an innovative combination of gene-editing tools and computational simulations that can be used to develop new strategies for editing genes associated with genetic disorders. Photo: Stephanie Precourt

Sahas team published its findings Dec. 8 in the journal Nature Communications.

In the first few months of life, an infant with Pompe disease becomes weaker and weaker as glycogen builds up in their muscles, their cells unable to break the complex sugar down. Multiple mutations in a gene calledGAAprevent their cells from correctly producing the proteins needed to make lysosomes, which turn glycogen into glucose, the fuel that powers cells. Left untreated, most patients with Pompe die within a year.

Developing effective therapies for such diseases can be difficult for a number of reasons. First, diseases like Pompe have no animal models in which to test treatments, a typical step in therapy development. And diseases like Pompe and many other inherited diseases are autosomal recessive, which means that mutations are present on both copies of a chromosome. Two sets of mutations require two successful gene-repair events for maximum effect. Further complicating the matter is the fact that many diseases are polygenic, resulting from mutations in two or more genes or multiple mutations spread across a single gene, as is the case for Pompe disease.

The Saha labs new approach uses precise gene-editing tools to edit both faulty alleles simultaneously within individual cells to restore function. In its new report, the research team used induced pluripotent stem cells derived from Pompe patients to reproduce the exactGAAmutations that cause the disease and to approximate the resulting tissue pathology.

To fix these Pompe mutations, the lab turned to a specially designed, ultra-precise genome-editing system described in aprevious studyled by Jared Carlson-Stevermer, who was at the time a graduate student in Sahas group. That report established an up to 18-fold increase in precision of gene edits by combining a DNA repair template with the cutting machinery of CRISPR in one particle.

In the current study, the researchers used the method to fix two mutations at once in Pompe-derived cells. By doing so, the researchers improved cell function dramatically, bringing lysosome protein production up to the level of healthy cells without any major adverse effects, which sometimes emerge from gene editing.

The research advances the CRISPR genome-editing field and could lead to effective treatments for many diseases.

But treating cells in the laboratory, while providing crucial insight, is not the same as creating a therapy for patients. A critical step in developing treatments usually involves testing on animal models to evaluate efficacy and safety, a major obstacle for Pompe disease and other genetic conditions that lack viable animal models.

To determine the best therapeutic strategy for polygenic diseases evaluating different doses, delivery mechanisms and timing, risks and other factors the research team instead built a computational model that allows it to predict the outcomes of various conditions.

This allows us to survey a wider scope of many different gene therapies during the design of a strategy, says coauthor Amritava Das, a postdoctoral associate at the Morgridge Institute for Research. The computational approach is critical when you dont have an animal model that resembles the human disease.

After pumping close to a million simulation conditions through the computational model, Das, Carlson-Stevermer and Saha have gained key insights about the delivery of gene editors into the livers of human infants with Pompe disease without having to subject a single patient to experimental treatments. And those insights establish that the multiple-correction genome-editing approach tested in stem cells may be an effective treatment for Pompe and other polygenic recessive disorders.

The computational model, which can be easily adapted for other polygenic conditions, is a big step for the development of therapies for diseases like Pompe and lays the groundwork for a bridge from laboratory studies to the clinic. And as more measurements are added to the model, it will gain more predictive power.

Its a very broad, adaptable platform, Das says about the combined stem cell model and computational tool, and a very different way of thinking about gene therapy.

This work was supported by the National Science Foundation (CBET-1350178, CBET-1645123), the National Institutes of Health (1R35GM119644-01), the Environmental Protection Agency (EPA-G2013 STAR-L1), the University of Wisconsin Carbone Cancer Center (P30 CA014520), the Wisconsin Alumni Research Foundation, and the Wisconsin Institute for Discovery.

Follow this link:
Multiple gene edits and computer simulations could help treat rare genetic diseases - University of Wisconsin-Madison

ByHub staff report

Five Johns Hopkins faculty members have been elected as fellows of the National Academy of Inventors, a prestigious distinction that recognizes and honors the creators or co-developers of outstanding inventions that have made a difference in society. These professors join the more than 4,000 current fellows of the academy, which features members of more than 250 institutions worldwide.

The honorees from Johns Hopkins are:

Ramalingam Chellappa, who joined the Hopkins Department of Biomedical Engineering and the Department of Electrical and Computer Engineering as a Bloomberg Distinguished Professor earlier this year. Chellappa's work has shaped the field of facial recognition technology, and he is known as an expert in machine learning. At Hopkins he contributes to the Mathematical Institute for Data Science and the Center for Imaging Science.

Valina Dawson, a professor of neurology, neuroscience, and physiology in the School of Medicine, and co-director of the Neuroregeneration and Stem Cell Programs in the Institute for Cell Engineering. The lab aims to discover and describe the cell signaling pathways that contribute to neuron survival and death in Parkinson's disease and strokes. In her work, Dawson has discovered new therapies to treat neurological disorders, and established new neurological targets for patients' recovery processes.

Sharon Gerecht, professor of chemical and biomolecular engineering, and director of the Johns Hopkins Institute for NanoBioTechnology. Gerecht is an internationally recognized expert in vascular and stem cell biology and a member of the National Academy of Medicine. Together with her research group, she studies the interactions between stem cells and their microenvironments with the long-term goal of engineering artificial cell microenvironments.

Carol Greider, a professor in the Department of Molecular Biology and Genetics. In 2009, Grieder shared the Nobel Prize in Physiology or Medicine with Elizabeth Blackburn and Jack Szostak for their work on telomeres and telomerase, an enzyme that maintains protective "caps" on the ends of chromosomes. She studies the roles these enzymes play in cancer and age-related degenerative disease.

Nitish Thakor, a professor in the Department of Biomedical Engineering. Thakor conducts research on neurological instrumentation, biomedical signal processing, micro and nanotechnologies, neural prosthesis, and neural and rehabilitation techniques. Director of the Laboratory for Neuroengineering, Thakor also serves as director of the NIH Training Grant on Neuroengineering. Currently, he is developing a next-generation neurally controlled upper limb prosthesis alongside a multi-university consortium funded by DARPA.

Read the rest here:
Five Johns Hopkins faculty named to National Academy of Inventors - The Hub at Johns Hopkins

DUBLIN--(BUSINESS WIRE)--The "Europe Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Material Type, Applications, and Country" report has been added to ResearchAndMarkets.com's offering.

The Europe tissue engineering market is expected to reach US$ 7,368.93 million by 2027 from US$ 2,798.86 million in 2019; it is estimated to grow at a CAGR of 13.2% during 2020-2027.

The market growth is primarily attributed to the increasing incidences of chronic diseases, road accidents, and trauma injuries, and technological advancements in 3D tissue engineering techniques. High cost associated to the tissue engineering process is one of the major factors restraining the growth of the market. Additionally, increasing financial contributions by government and private sector are likely to fuel the growth of the Europe tissue engineering market during the forecast period.

Tissue engineering is a blend of material methods and cellular activities. This approach involves the use of physicochemical and biochemical attributes of humans to replace the biological tissues and strengthen them. It is an innovative technology that works either separately or in conjunction with scaffolds, stem cells, regenerative medicine, and growth factors or negotiators. The process utilizes molecular and cellular processes in combination with the principles of material engineering to surgically repair and restore tissue.

The tissue engineering market in Europe is estimated to grow at a significant CAGR during the forecast period, and the growth is driven by the increase in research activities, growing demand for organ transplants, escalating number of initiatives by market players for expanding their presence in the region, and higher adoption of stem cell research in several European countries.

In the Europe, due to an increasing number of COVID-19 patients, healthcare professionals and leading organizations are rechanneling the flow of healthcare resources from R&D to primary care, which is slowing down the process of innovation. Further, the pandemic is also hindering the conduct of clinical trials and drug development, and the operations of diagnostic industry in Europe.

For instance, Stryker Corporation, a well-known player in the tissue engineering industry, has diverted operations to manufacture COVID-19 diagnostics and PPE kits. Moreover, according to a recent survey published by Medscape in July 2020, substantial disruption has been witnessed in routine research activities that include tissue engineering and regenerative medicines as a result of the COVID-19 pandemic. The rapid increase in the number of the infected patients in the Italy and Spain is likely to result in the slowdown of the market growth in the near future.

In 2019, the biologically derived material segment accounted for the largest share of the Europe tissue engineering market. The growth of the market for this segment is attributed to the rising adoption of biomaterials due to their natural regenerative potential to restore tissue functioning and ability to facilitate the on demand release of chemokines with the procedure. Further, the synthetic material segment is likely to register the highest CAGR in the market during the forecast period.

Key Topics Covered:

1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

1.3 Market Segmentation

2. Europe Tissue engineering Market - Key Takeaways

3. Research Methodology

4. Europe Tissue engineering Market - Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinion

5. Europe Tissue engineering Market - Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Increasing Number of Road Accidents and Trauma Injuries, and Elevating Incidence of Chronic Diseases

5.1.2 Technological Advancements in the Field of 3D Tissue engineering

5.1.3 Government and Private sector funding

5.2 Key Market Restraints

5.2.1 High Cost associated with tissue engineering

5.3 Impact Analysis

6. Tissue engineering Market - Europe Analysis

6.1 Europe Tissue engineering Market Revenue Forecasts and Analysis

7. Europe Tissue engineering Market Analysis - By Material Type

7.1 Overview

7.2 Europe Tissue engineering Market, By Material Type 2019-2027 (%)

7.2.1 Europe Tissue engineering Market Material Type Segment Revenue and Forecasts to 2027, By Material Type (US$ Mn)

7.3 Biologically Derived Material

7.4 Synthetic Material

7.5 Other

8. Europe Tissue engineering Market Analysis - By Application

8.1 Overview

8.2 Europe Tissue engineering Market, By Application 2019-2027 (%)

8.2.1 Europe Tissue engineering Market Revenue and Forecasts to 2027, By Application (US$ Mn)

8.3 Orthopedic, Musculoskeletal and Spine

8.3.1 Overview

8.3.2 Europe Orthopedic, Musculoskeletal and Spine Market Revenue and Forecasts to 2027 (US$ Mn)

8.4 Skin

8.5 Cardiology and Vascular

8.6 Neurology

8.7 Others

9. Europe Tissue engineering Market Revenue and Forecasts To 2027 - Regional Analysis

10. Impact of COVID-19 Pandemic on Europe Tissue Engineering Market

10.1 Europe: Impact Assessment of COVID-19 Pandemic

11. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/ppygkp

Read the original post:
Europe Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Material Type, Applications, and Country -...

Social media is buzzing with the claim President Trump, who is pro-life, used an antibody cocktail developed using human embryonic stem cells.

The antibody cocktail used to treat President Donald Trump for COVID-19 is getting a lot of attention on social media.

Some users are claiming Regeneron - the company that developed the treatment - used human embryonic stem cells to create it, but is this true?

News 8 reached out to Regeneron for comment.

"This particular discovery program (regn-cov2) did not involve human stem cells or embryonic stem cells," wrote Regeneron spokesperson Alexandra Bowie in a statement.

So, where did that claim about human embryonic stem cells come from?

It appears to have developed from this statement Regeneron issued back in April 2020 regarding stem cell research:

"As is the case with many other science-focused biotechnology companies, Regeneron uses a wide variety of research tools and technologies to help discover and develop new therapeutics. stem cells are one such tool. the stem cells most commonly used at Regeneron are mouse embryonic stem cells and human blood stem cells. currently, there are limited research efforts employing human-induced pluripotent stem cell lines derived from adult human cells and human embryonic stem cells that are approved for research use by the national institutes of health and created solely through in vitro fertilization."

According to the American Association for the Advancement of Science, here's what the antibody cocktail used to treat the president is made of:

"One antibody comes from a human who had recovered from a SARS-COV-2 infection; a B cell that makes the antibody was harvested from the person's blood and the genes for the immune protein isolated and copied. The other antibody is from a mouse, which was engineered to have a human immune system, that had the spike protein injected into it."

Bowie also told News 8 the statement about stem cell research on its website reflects the company's general position on stem cell research, but does not mean human embryonic stem cells were used in creating the antibody cocktail used to treat the president.

Nevertheless, some said the company's position on using stem cells in general contradicts President Trump's pro-life stance and that of Supreme Court Nominee Amy Coney Barrett.

But the bottom line, were human embryonic stem cells used in Regeneron's antibody cocktail to treat the president? News 8 can verify the answer is no.

Read the original here:
VERIFY: Was the antibody cocktail used to treat President Trump developed using human embryonic stem cells? - CBS News 8

California voters are once again considering the issue of stem cell research.

After approving spending $3 billion on the work in 2004, taxpayers are being asked for another $5.5 billion under Proposition 14.

Some of the initial funding was used to create the California Institute for Regenerative Medicine which would get more money if the measure passes.

"Prop 14 is targeted at treating and curing curable diseases that we all care about," said Dr. Larry Goldstein, a professor at UC San Diego, and the Scientific Director for the Sanford Consortium for Regenerative Medicine.

He a supporter of Prop 14, along with the California Democratic Party and the UC Board of Regents.

He says the funding is necessary to save lives.

"We lose family members prematurely to terrible diseases like cancer and Alzheimer's Disease," said Goldstein.

Proposition 14's total cost to tax payers, including interest on the general obligation bonds, is $7.8 billion according to the state legislate analyst.

That breaks down to $280 million a year over 30 years, with the money coming from the state general fund.

The highest profile opponent of Prop 14 points to what they call a "lack of legislative oversight" of the California Institute for Regenerative Medicine.

They also say the state budget deficit is already too high.

That opponent is the Oakland-based "Center for Genetics and Society".

Another opponent has close ties to the California Institute for Regenerative Medicine.

Jeff Sheehy is a member of the agency's Citizen's Oversight Committee.

"We have a lot of needs that are more pressing than stem cell research which is well funded by the federal government," said Sheehy.

Sheehy contends state funding for scientific research should be up to the state legislature.

"You don't vernally pay for programs like this with debt," said Sheehy.

ANALYSIS OF PROPOSITION 21 FROM BALLOTPEDIA:

https://ballotpedia.org/California_Proposition_14,_Stem_Cell_Research_Institute_Bond_Initiative_(2020)

Go here to see the original:
Proposition 14 would authorize state to borrow $5.5 billon for stem cell research - KESQ

Remember how urgent it was to support embryonic stem cell research? That was then; this is now

The hot button bioethical issue of 2004 was embryonic stem cell research. Supporters spoke of life-saving cures and dismissed ethical misgivings. Surfing a wave of hope, Californian voters voted for a US$3 billion bond issue to establish the California Institute for Regenerative Medicine.

Sixteen years later, the CIRM has almost run out of money and its backers are rattling the tin in the hope that voters will approve a $5.5 billion bond issue to support its research.

Some of the states major newspapers have editorialised against it. With many of its critics, they contend that the CIRM has not delivered on its miracle cures, that its governance has been poor and that there was too much potential for conflict of interest.

The Los Angeles Times decried the earlier over-sell:

[The CIRM] hasnt yet yielded a significant financial return on investment for the state or the cures that were ballyhooed at the time. Though no one ever promised quick medical miracles, campaign ads strongly implied they were around the corner if only the funding came through. Proponents oversold the initiatives and voters cant be blamed if they view this new proposal with skepticism.

The San Francisco Chronicle, which exposed some of the CIRMs deficiencies in a 2018 expos, criticised the way its funds had been spent:

More than half the original funding went to buildings and other infrastructure, education and training, and the sort of basic research that, while scientifically valuable, is a long way from medical application. Theres nothing inherently wrong with that, but it is at odds with the vision of dramatic advancements put to voters."

Michael Cook is editor of BioEdge

Continue reading here:
Remember how urgent it was to support embryonic stem cell research? That was then; this is now - BioEdge

Advances in the stem cell therapy sector have been phenomenal over the years. Its assistance in curing humans of various diseases and disorders has generated expansive advancements. These advancements are not just limited to humans. Stem cell therapy has also acquired a prominent place in the veterinary sector.

The influence of animal stem cell therapy for the treatment of various animals for diverse diseases and disorders is growing rapidly. Therefore, this factor may help the global animal stem cell therapy market to generate exponential growth across the forecast period of 2019-2029. Stem cells help in the replacement of neurons affected by stroke, Parkinsons disease, spinal cord injury, Alzheimers disease, and others.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6816

This animal stem cell therapy market report has extensive information on various aspects associated with bringing growth. Important factors such as emerging trends, mergers and acquisitions, and the regional scenario of the animal stem cell therapy market have been analyzed and included in the report. The stakeholders can derive a treasure of information from this report. This report also includes a scrutinized take on the COVID-19 impact on the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Competitive Prospects

The competitive landscape of the animal stem cell therapy market can be described as mildly fragmented. With a considerable chunk of players, the animal stem cell therapy market is surrounded by substantial competition. Research and development activities form an important part of the growth landscape because they help gain novel insights.

Activities such as mergers, acquisitions, joint ventures, collaborations, and partnerships form the foundation of the growth of the animal stem cell therapy market. These activities help manufacturers to gain influence and eventually help in increasing the growth rate of the animal stem cell therapy market. Prominent participants in the animal stem cell therapy market are Magellan Stem Cells, Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc., Celavet Inc., VETSTEM BIOPHARMA, and VetCell Therapeutics.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6816&ltype=S

Animal Stem Cell Therapy Market: Key Trends

Infections are scaling up among animals at a rapid rate. The alarming increase is proving fatal for many animals. Therefore, to avoid such incidences and treat existing diseases and disorders, animal stem cell therapy is being applied seamlessly. Hence, this aspect may bring great growth opportunities for the animal stem cell therapy market.

Developments have been observed across the animal stem cell therapy market for long. Autologous adipose-derived mesenchymal stem cells are gaining traction for successfully resolving a range of issues in animals. These stem cells help in treating ligament and tendon injuries to a certain extent. The strengthening influence of this stem cell type in companion animals is also proving to be a prominent growth prospect for the animal stem cell therapy market.

Recent research has also found that stem cell-derived CC exosomes showed improved recovery from myocardial infarction (MI) among pigs. Such developments assure promising growth for the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Regional Analysis

The animal stem cell therapy market is spread across North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The animal stem cell therapy market may derive significant growth from North America. The escalating awareness regarding animal stem cell therapy may attract profound growth. Strengthening research and development activities in the region regarding animal stem cell therapy is further expanding the growth prospects.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6816

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Continue reading here:
Animal Stem Cell Therapy Market - Great Growth Opportunities for the Market in the Coming Year | TMR Research Study - BioSpace

during the forecast period. Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products.

New York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regenerative Medicine Market by Product, Application, Geography - Global Forecast to 2025" - https://www.reportlinker.com/p04700208/?utm_source=GNW However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast periodBased on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies.The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019.

The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGRBased on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications.In 2019, the oncology segment accounted for the highest growth rate.

This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine marketThe global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World.The North America region is projected to grow at the highest CAGR during the forecast period in 2019.

The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The primary interviews conducted for this report can be categorized as follows: By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35% By Designation: C-level - 30%, D-level - 20%, and Others - 50% By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World 12%

Lits of companies Profiled in the Report: 3M (US) Allergan plc (Ireland) Amgen, Inc. (US) Aspect Biosystems (Canada) bluebird bio (US) Kite Pharma (US) Integra LifeSciences Holdings Corporation (US) MEDIPOST Co., Ltd. (South Korea) Medtronic plc (Ireland) Anterogen Co., Ltd. (South Korea) MiMedx Group (US) Misonix (US) Novartis AG (Switzerland) Organogenesis Inc. (US) Orthocell Limited (Australia) Corestem, Inc. (South Korea) Spark Therapeutics (US) APAC Biotech (India) Shenzhen Sibiono GeneTech Co., Ltd. (China) Smith & Nephew plc (UK) Stryker Corporation (US) Takeda Pharmaceutical Company Limited (Japan) Tego Science (South Korea) Vericel Corporation (US) Zimmer Biomet (US)

Research Coverage:This report provides a detailed picture of the global regenerative medicine market.It aims at estimating the size and future growth potential of the market across different segments, such as product, application, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies.

This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and trends.

Read the full report: https://www.reportlinker.com/p04700208/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See more here:
The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% - Yahoo...

Parkinsons is a progressive neurodegenerative disorder that characteristically affects the dopamine-producing neurons in the substantia nigra or the midbrain. It usually begins with stiffness, shaking, tremors, voice changes, and postural instability, all of which worsen with time, resulting in difficulty walking and talking.

Man With Parkinsons

Parkinsons is a widely common neurodegenerative disease affecting approximately 10 million people worldwide, as of 2019. And the rate of incidence increases with age, for example, it affects 1 percent of individuals over the age of 60 years in comparison to 5 percent of individuals over the age of 85 years.

Read Also: Parkinsons Disease: A Promising Treatment Thanks to Stem Cells

Parkinsons is a nervous system disorder that predominantly affects the motor function of the patient, therefore reducing the quality of life significantly. Unfortunately, Parkinson does not have a cure but there are many supportive therapeutic options available for the patients in the form of physical therapy, and medication along with a treatment option including deep brain stimulation (DBS).

DBS has shown great results but it is an invasive procedure that only produces temporary results. Hence, more research and studies need to be performed in the field of nervous system disorders to discover better therapeutic approaches.

Parkinsons and other nervous system disorders like stroke, Huntingtons, and so on are difficult to cure or treat due to the extensive damage to the neurons seen in these diseases. This is a problem because neurons are infamous for their inability to regenerate. Although stem cells that can be adapted into neurons may be recommended as a therapeutic option, they come with a problem of their own.

The new neurons do not connect with the native neurons as they do not recognize or identify them. This results in no improvement in neuronal circuitry and in the patients condition.

A recent study published in Cell Stem Cell Journal by Su-Chun Zhang, Department of Neuroscience, School of Medicine and Public Health, University of Wisconsin-Madison, and her team claim to have derived neurons from human stem cells that can be used to repair circuitry and improve neural functions.

Read Also: Antibiotics May Increase Your Risk of Having Parkinsons Disease

Zhang and her team derived dopamine-producing neurons from human embryonic stem cells and then transplanted these into the substantia nigra of the brain in animal models with Parkinsons disease.

These transplanted cells also contained on and off switches that could be stimulated externally using certain drugs or foods.

Zhang and her team found that these transplanted cells formed connections with native neurons and grew long-distance to form connections with the motor control regions in the brain to improve the motor functions usually affected by Parkinsons. The results were visible after a few months of transplantation, the time needed for the transplanted neurons to integrate into the brain.

To confirm that the improvement seen in the mice was due to the transplanted cells, the on and off switches were stimulated by the research team.

Read Also: Implants from Own Stem Cells May Offer Solution to Back Pain, Researchers Say

When the cells were turned off, the symptoms of Parkinsons reappeared indicating the proper functioning of these cells in the treatment of the neurodegenerative disorder. Furthermore, the scientists on closer look found that these cells were identified by native neurons and had been integrated into the midbrain. Moreover, the researchers believe that these switches can be used to fine-tune the treatment option for the patients.

The research team is currently applying these results to the primates model and aims to use the results from Parkison disease models for other nervous system disorders as well.

Human Stem Cell-Derived Neurons Repair Circuits and Restore Neural Function

Medical University of Vienna: Vitamin B1 May Help Prevent Alcohol-Related Dementia

Old Human Cells Successfully Rejuvenated Via Stem Cell Technology

Is NAD+ The Anti Aging Substance Mankind Has Been Searching For?

Anti-Aging: A New Way to Repair Age Related DNA Damage Discovered

Anti-Aging: HGH Can Reduce Biological Age by One Year and a Half Study Shows

Genf20 Plus Review: Why Are People Rushing to Buy This HGH Supplement?

University of Utah: Could Slowing the Rate of DNA Mutations Be the Key to the Elusive Fountain of Youth

Excerpt from:
University of Wisconsin Researchers Use Stem Cells to Treat Parkinson's - Gilmore Health News